<SEC-DOCUMENT>0001193125-23-156899.txt : 20230531
<SEC-HEADER>0001193125-23-156899.hdr.sgml : 20230531
<ACCEPTANCE-DATETIME>20230530201857
ACCESSION NUMBER:		0001193125-23-156899
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230530
FILED AS OF DATE:		20230531
DATE AS OF CHANGE:		20230530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23978608

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d524540d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;30, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d524540dex991.htm">Immutep Selects Charles River Laboratories for IMP761&#146;s GLP Toxicology Study </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;30, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d524540dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;99.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g524540g62v06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Selects Charles River Laboratories for IMP761&#146;s GLP Toxicology Study </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appointment of Charles River Laboratories (&#147;Charles River&#148;) to run Immutep&#146;s preclinical
toxicology study evaluating the safety and toxicity of IMP761 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forms a key step prior to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials for this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
<FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody designed to treat the underlying cause of multiple autoimmune diseases </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Charles River is a highly respected, global provider of drug discovery and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> development solutions operating more than 110 sites across more than 20 countries </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 29&nbsp;May 2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with Charles River under which Charles River will
conduct a GLP toxicology study for IMP761, Immutep&#146;s proprietary preclinical candidate for autoimmune diseases. IMP761 is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT
STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody that aims to address the underlying cause of many autoimmune diseases, namely the overactivation of self-antigen-specific memory T cells expressing
<FONT STYLE="white-space:nowrap">LAG-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical toxicology studies are an essential part of drug development as they help to evaluate the
potential safety and toxicity of a drug candidate before it is tested in humans. With its well-established expertise assisting companies in early-stage drug development, Charles River is the partner of choice to help progress our IMP761 program
through this key stage of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Immutep is continuing its pioneering work in the <FONT
STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy landscape, as we advance IMP761, the world&#146;s first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, towards the clinic in the first half of next year. With its novel ability
to enhance the signalling of the <FONT STYLE="white-space:nowrap">LAG-3</FONT> inhibitory receptor and down-regulate auto-reactive memory T cells at the centre of many autoimmune diseases, we believe IMP761 has the potential to change how immune
disorders are treated. We are pleased to be working with an established global company like Charles River for this next important step of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development,&#148; stated Immutep&#146;s Chief
Scientific Officer, Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761&#146;s agonistic activation of <FONT STYLE="white-space:nowrap">LAG-3</FONT> is
relevant for many diseases, including the <FONT STYLE="white-space:nowrap">Th1-driven</FONT> autoimmune disease setting. In a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> oligoarticular juvenile idiopathic arthritis model IMP761 decreased
secretion of nearly all measured cytokines, and several key cytokines <FONT STYLE="white-space:nowrap">(IL-10,</FONT> <FONT STYLE="white-space:nowrap">IL-12,</FONT> <FONT STYLE="white-space:nowrap">IL-1&szlig;,</FONT>
<FONT STYLE="white-space:nowrap">IL-4,</FONT> and <FONT STYLE="white-space:nowrap">IL-6)</FONT> reached the level of statistical-significance (p&nbsp;&lt;&nbsp;0.01). These results were published in&nbsp;<U>Pediatric&nbsp;Research</U>&nbsp;in May
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GLP (Good Laboratory Practice) toxicology results and other preclinical studies will be an essential part of the Company&#146;s clinical trial
application for IMP761. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by
specifically silencing autoimmune memory T cells that accumulate at </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g524540g62v06.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">disease sites. These T cells express <FONT
STYLE="white-space:nowrap">LAG-3</FONT> as an &#147;exhaustion marker&#148; after being repeatedly stimulated with dominant self-peptides. As published in the&nbsp;<U>Journal of Immunology</U>&nbsp;in January 2020, encouraging <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> results were achieved with IMP761 leading to significant inhibition of inflammatory T cell infiltration. Additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> findings published
in&nbsp;<U>Pediatric&nbsp;Research</U>&nbsp;in May 2021 show IMP761 led to large decreases in effector T cell cytokine secretion in a juvenile arthritis model. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g524540g62v06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g524540g62v06.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@!,B@!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H 0T <5XA\179DDAL-Z01-L>91U;T![5A.;V1PUJTMHF';37\C1NE],L
MCRA%R[<D]\U"OW.>/.^IV^F:E,E\^E7TB27**&61. X]QV-;Q;O9GH0G[W)+
M<VA5FPM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 5I]1L[6>.">ZBBED^XCN 6^@H LB@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * &2Y\MMOWL<4A/8\NL+YX9X[>X?\ T1I0TL;#
M(//)KF3U/*A-J=GL=]K#6J:-,K-&F8R(^0/FQQBMWRV/0J<O)8XG089X?$UK
M$RE9%<A@>PP<_I6$-)'#1NJJN>F"NH]0* "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H #TH
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MM"Y6/' H Z;Q^''A?31(")!(NX'UV&@#1^'G_(KK_P!=G_I0!%\1XD;PY&[
M;TG7;^(.: (OAH['0[I2256X./\ OD9H [6@ H * "@ H * "@ H * "@ H
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M)DD]F/;\!@4 ;E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M6@#J;'0],TU]]I90Q/\ W@OS?GUH T* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *=M([WEXK,2J.H4>GR@
M_P!: *5SJ;1:LH7?]GB98Y,(2I+=R<8&/E[]S0!*[&XO[I))I(XX%4JD;;2<
MC.[CD^GIP: +<=P'6((DA21 P?' 'O0!5M6DBU>6W=I/+:/>@=]V[!Y/MU'%
M $]S(Z7]FBL0KEMP]<+0!FQWUVK31%B[W$LBV[$<)ARI!]@!N]^10 GVN[%I
MILD<C.XB,LJXYD"A01]>2?J!0!8L;J6XU"5RY^SRQ!H5QT )&[\<Y^F* "WN
MI7M-&8RDM-CS#_>_=,3G\0* *EU?W5K;ZE*\A,>YTC?O$P' ^A_G]> #0F+7
M&J?96E>.)80X"-M+DD@\CGC Z?WJ (XC)-972M/(?(D=4E5L%@!WQZ$D?A0
MTR30:?ISHTDKR.FX%N6RI)&30 V>[N?LNKL0T3PP[HQD':=A.>/>@"64S6^D
MWTN)HY%B9E+R;R"%/(H 33YI?M\L9\Y(TC4E)V!.2>H()XZ]Z (K'4WEU ,[
M2&"ZW"(-&0J[?NX)'.X9/X4 )$UW+<NT7GY6Y*EBP\O8&Y&,YZ>@ZT 3QM='
M43:&0^6A\[S,\E23A/S!_ #UH Y_XE_\@.T_Z^!_Z": +7P\_P"177_KL_\
M2@#JZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(@8 ^O- #K:TM[*+RK6".&/.=L:A1GZ"@":@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M (2K6?\ G[_\AK_A1[20>WJ!_P )5K/_ #]_^0U_PH]I(/;U _X2K6?^?O\
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M;U _X2K6?^?O_P AK_A1[20>WJ!_PE6L_P#/W_Y#7_"CVD@]O4#_ (2K6?\
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M_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\
MGTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L
M^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/
M8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5
M=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]
MBCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?
M2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[
M+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@
M_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V
M#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*
M.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](
M?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO
M^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^
MS[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.
M2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY
M5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_
M[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y
M](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/
MLO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(
M]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE7
M8.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_O
MV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GT
MA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R
M_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8HY5V#DCV
M#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'_OV*.5=@
MY(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_ )](?^_8
MHY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/[/LO^?2'
M_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#DCV#^S[+_
M )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BCE78.2/8/
M[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^_8HY5V#D
MCV#^S[+_ )](?^_8HY5V#DCV#^S[+_GTA_[]BCE78.2/8/[/LO\ GTA_[]BC
ME78.2/8/[/LO^?2'_OV*.5=@Y(]@_L^R_P"?2'_OV*.5=@Y(]@_L^R_Y](?^
9_8HY5V#DCV%%A9CI:PC_ ( *.5#Y(]C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
